KRN 633|2mg|K1383-上海高创化学科技有限公司

SKU:K1383		M. Wt:416.86
Formula:C20H21ClN4O4		Solubility:No
Purity:>99%		Storage:2 years at -20 degrees centigrade
CAS No.:286370-15-8		Synonyms:N/A
Chemical NameN/A

Description	KRN 633
Targets	VEGFR-2
IC50	1.16 nM
In vitro	KRN633 can inhibit tyrosine phosphorylation of VEGFR-2 with IC50 of 1.16 nM in human umbilical vein endothelial cells.KRN633 is highly selective for VEGFR-1, VEGFR-2, and VEGFR-3. KRN633 also can block the activation of mitogen-activated protein kinases by VEGF, along with human umbilical vein endothelial cell proliferation and tube formation. The propagation of various cancer cell lines in vitro was not inhibited by KRN633.[1] KRN633 also shows suppression on HIF-1alpha accumulation under the hypoxic condition. The VEGFR tyrosine kinase inhibitors, KRN633, possess dual functions:inhibition of VEGFR signaling and HIF-1alpha expression under the hypoxic condition. KRN633 suppresses HIF-1alpha expression through inhibition of both Akt and ERK phosphorylation signaling pathways.[2] Administration of KRN633 can decreases the alkaline phosphatase (ALP) activity during the osteoblastic differentiation of cultured human periosteal-derived cells.[3]
In vivo	P.o. administration of KRN633 inhibits tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN633 also causes the regression of some well-established tumors and those that has regrown after the cessation of treatment. In these models, the trough serum concentration of KRN633 has a more significant effect than the maximum serum concentration on antitumor activity. Tumor xenografts treated with KRN633 shows a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability. KRN633 is well tolerated and had no significant effects on body weight or the general health of the animals. [1]Pregnant mice daily treated with the VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor KRN633 (300 mg/kg, p.o.) suppresses vascular growth of both the placenta and fetus without obvious health impairments of mother mice and increases the risk of induction of intrauterine growth restriction.[3]
Clinical Trials	N/A
Features	N/A

Description

KRN 633

Targets

VEGFR-2

IC50

1.16 nM

In vitro

KRN633 can inhibit tyrosine phosphorylation of VEGFR-2 with IC50 of 1.16 nM in human umbilical vein endothelial cells.KRN633 is highly selective for VEGFR-1, VEGFR-2, and VEGFR-3. KRN633 also can block the activation of mitogen-activated protein kinases by VEGF, along with human umbilical vein endothelial cell proliferation and tube formation. The propagation of various cancer cell lines in vitro was not inhibited by KRN633.[1] KRN633 also shows suppression on HIF-1alpha accumulation under the hypoxic condition. The VEGFR tyrosine kinase inhibitors, KRN633, possess dual functions:inhibition of VEGFR signaling and HIF-1alpha expression under the hypoxic condition. KRN633 suppresses HIF-1alpha expression through inhibition of both Akt and ERK phosphorylation signaling pathways.[2] Administration of KRN633 can decreases the alkaline phosphatase (ALP) activity during the osteoblastic differentiation of cultured human periosteal-derived cells.[3]

In vivo

P.o. administration of KRN633 inhibits tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN633 also causes the regression of some well-established tumors and those that has regrown after the cessation of treatment. In these models, the trough serum concentration of KRN633 has a more significant effect than the maximum serum concentration on antitumor activity. Tumor xenografts treated with KRN633 shows a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability. KRN633 is well tolerated and had no significant effects on body weight or the general health of the animals. [1]Pregnant mice daily treated with the VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor KRN633 (300 mg/kg, p.o.) suppresses vascular growth of both the placenta and fetus without obvious health impairments of mother mice and increases the risk of induction of intrauterine growth restriction.[3]

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

KRN 633由上海高创化学科技有限公司为您提供，货号K1383，规格：2mg，CAS号：286370-15-8，如您想了解更多关于KRN 633价格、KRN 633结构式、批发、用途等信息，欢迎咨询。除供应KRN 633外，还可为您提供大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit、重组人半乳糖凝集素8/Human LGALS8 His、重组人肌球蛋白轻链2(Recombinant Human MYL2)等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。